Recent News

• 02.12.2025 - Portage Biotech Receives Extension of Time to Attain Compliance With Stock Exchange Continued Listing Requirements
• 02.12.2025 - Portage Biotech Receives Extension of Time to Attain Compliance With Stock Exchange Continued Listing Requirements
• 01.30.2025 - Portage Biotech Announces Completion of $2.15 Million Private Financing
• 01.30.2025 - Portage Biotech Announces Completion of $2.15 Million Private Financing
• 01.06.2025 - Portage Biotech Announce Re-Launch of Adenosine Subsidiary as Independently Managed Company; Appointment of Peter Molloy to Lead New Company
• 01.06.2025 - Portage Biotech Announce Re-Launch of Adenosine Subsidiary as Independently Managed Company; Appointment of Peter Molloy to Lead New Company
• 12.17.2024 - Portage Biotech Announces Letter of Intent with Immunova for an Option to Acquire iOx Therapeutics, Ltd
• 12.17.2024 - Portage Biotech Announces Letter of Intent with Immunova for an Option to Acquire iOx Therapeutics, Ltd

Recent Filings

• 02.12.2025 - EX-99.1 EX-99.1
• 02.12.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 02.12.2025 - 424B3 Prospectus [Rule 424(b)(3)]
• 01.31.2025 - SCHEDULE 13D/A General Statement of Acquisition of Beneficial Ownership
• 01.31.2025 - SCHEDULE 13D/A General Statement of Acquisition of Beneficial Ownership
• 01.30.2025 - EX-99.1 EX-99.1
• 01.30.2025 - 424B3 Prospectus [Rule 424(b)(3)]
• 01.30.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 01.06.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 01.06.2025 - EX-99.1 EX-99.1